03.09.2012 - EU-funded researchers will use a €6m grant to develop cost-effective molecular diagnostics (MDx) tools for the rapid diagnosis of infections.
The aim is to come up with a test that would reduce the diagnosis time of respiratory tract infections from days to hours, so that the appropriate treatments can be administered as early as possible, giving patients the best possible chance of a swift recovery. These diagnostic products will be based on a novel "sample-in, result-out" technology platform. The project, titled RID-RTI ('Rapid Identification of Respiratory Tract Infections'), brings together researchers from small and medium-sized enterprises (SMEs), universities and hospitals. The Molecular Diagnostics Research Group at the National University of Ireland, Galway; French diagnostics firm Genewave; Finnish biotech company Mobidiag; Assistance Publique Hopitaux de Paris; and University College London are part of the consortium. They receive a €6m boost of funding from the EU's Seventh Framework Programme (FP7). Respiratory tract infections, such as pneumonia, are amongst the top four major causes of morbidity and mortality worldwide. „Speed and accuracy are key to appropriate therapy and survival of the patient. The ultimate objective is to develop new cost effective, user-friendly products that will be routinely used in hospitals“, stated Thomas Barry from the Molecular Diagnostics Research Group at NUI Galway in Ireland. „This could replace time-consuming and labour-intensive methods so that a diagnosis can be achieved within a couple of hours, rather than days or weeks.“
18.09.2015 AstraZeneca has partnered up with the US Department of Health in order to accelerate the development of new antibiotics. The goal: to be prepared for multi-resistant bugs – and for bioterrorism.